UK chemoinformatics specialist De Novo has outsourced its hardware and software platform needs to Sun. Combining their expertise could allow them to create a valuable tool to research and development teams – although the success of this venture will depend on how well they can cooperate and integrate their skills.
De Novo has partnered with Sun Microsystems to create a comprehensive chemoinformatics platform.
UK chemoinformatics company De Novo and the US IT provider Sun Microsystems have joined forces. The joint venture is to co-develop a chemoinformatics platform to store designs of potential drugs generated by Skelgen, De Novo’s proprietary software. The collaboration allows De Novo to focus on its expertise in creating chemical structures, while Sun provides high-performance computing platforms.
If the technology is successful, De Novo will retain full rights for the commercial use of the design platform. As a technology development partner, Sun will receive certain rights to implement the created hardware solution within participating pharmaceutical company partners.
Given Sun’s background in providing high-performance computing and hardware, the prospect is likely to produce an improved chemoinformatics platform. Such a tool would be increasingly useful to the R&D efforts of pharmaceutical companies.
The completion of the Human Genome Project increased the number of potential drug targets greatly. As a result, the drug discovery process is more challenging and prospectively requires a larger platform to operate on. Increased computing power is, therefore, essential in maximizing the potential of a chemoinformatics strategy.
Pharmaceutical companies should keep track of the progress of this venture, especially while considering their own R&D needs and strategies. Whether they decide to establish a partnership with De Novo in order to use its new tool should be based on the progress of this collaboration.
The joint venture looks promising given that both De Novo and Sun already have established product offerings in their area of specialty. However, the profitability and success of the venture in the long run will depend on how effectively the companies integrate their respective products.